{
    "nct_id": "NCT03384238",
    "official_title": "A Phase I/II Study Evaluating the Safety and Pharmacokinetics of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Pancreas Cancer During Surgical Procedures",
    "inclusion_criteria": "* Clinically suspected or biopsy-confirmed diagnosis of pancreatic adenocarcinoma\n* Planned standard of care surgery with curative intent for pancreatic adenocarcinoma\n* Life expectancy of more than 12 weeks\n* Karnofsky performance status of at least 70% or Eastern Cooperative Oncology Group (ECOG)/Zubrod level =< 1\n* Hemoglobin >= 9 gm/dL\n* Platelet count >= 100,000/mm^3\n* Magnesium > the lower limit of normal per institution normal lab values\n* Potassium > the lower limit of normal per institution normal lab values\n* Calcium > the lower limit of normal per institution normal lab values\n* Thyroid-stimulating hormone (TSH) < 13 micro international units/mL\nHealthy volunteers allowed\nMust have minimum age of 19 Years",
    "exclusion_criteria": "* Received an investigational drug within 30 days prior to first dose of panitumumab-IRDye800\n* Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); or unstable angina within 6 months prior to enrollment\n* History of infusion reactions to panitumumab or other monoclonal antibody therapies\n* Pregnant or breastfeeding\n* Evidence of corrected QT (QTc) prolongation on pretreatment electrocardiography (ECG) (greater than 440 ms in males or greater than 460 ms in females)\n* Lab values that in the opinion of the physician would prevent surgical resection\n* Patients receiving class IA (quinidine, procainamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents",
    "miscellaneous_criteria": ""
}